Substituted thienyl stibines and bismuthines: syntheses, structures and cytotoxicity

New stibine and bismuthine substituted thienyl ring compounds, i.e. tris(3-methyl-2-thienyl)stibine (1), tris(3-methyl-2-thienyl)bismuthine (2), tris(3-thienyl)stibine (3), tris(3-thienyl)bismuthine (4) and tris(5-chLoro-2-thienyl)stibine (5), have been synthesized and characterized by IR, mass, H-1...

ver descrição completa

Detalhes bibliográficos
Autores: Sharma, P, Rosas, N, Cabrera, A, Toscano, A, Gutierrez, R, Hernández, MJS, Hernández, S
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2005
País:México
Recursos:Universidad Nacional Autónoma de México
Repositorio:Sistema de Información de la Facultad de Ciencias, UNAM
OAI Identifier:oai:repositorio.fciencias.unam.mx:11154/2368
Acesso em linha:http://hdl.handle.net/11154/2368
Access Level:acceso abierto
Palavra-chave:Chemistry, Applied
Chemistry, Inorganic & Nuclear
stibine
bismuthine
substituted thienyl
crystal structure
cytotoxicity
Descrição
Resumo:New stibine and bismuthine substituted thienyl ring compounds, i.e. tris(3-methyl-2-thienyl)stibine (1), tris(3-methyl-2-thienyl)bismuthine (2), tris(3-thienyl)stibine (3), tris(3-thienyl)bismuthine (4) and tris(5-chLoro-2-thienyl)stibine (5), have been synthesized and characterized by IR, mass, H-1, C-13, COSY, and HETCOR NMR spectroscopy. The metal centres in all compounds are pyramidal, and molecules in the stibine compound (1) and bismuthine compound (2) associate via Sb center dot center dot center dot S or Bi center dot center dot center dot S interactions to form supramolecular chains. The cytotoxicity of compounds 1 and 5 was determined. For compound 5, 85% of carcinogenic cell growth inhibition (U, K and H) was observed. Compound 1 shows a significant selectivity (> 80%) for carcinogenic cell growth (K and U) inhibition. Both the compounds are highly toxic for the growth of normal lymphocytes with similar to 95% lethality. Compound 1 is approximately 20 times more toxic than 5 against Artemia salina. Copyright (c) 2005 John Wiley & Sons, Ltd.